Clinical Trials

Locally Advanced Gastric or Gastroesophageal Junction Cancer

NCT03406299 2026-04-09

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

92 enrolled

Biliary Tract Neoplasms

NCT05184803 2026-04-07

A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

63 enrolled

Stomach Neoplasms

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

46 enrolled

Phase 3 Active not recruiting

Stomach Neoplasms

NCT05771480 2026-03-25

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT07492615 2026-03-25

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

276 enrolled

Stomach Neoplasms

NCT06256328 2026-03-13

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

226 enrolled

Stomach Neoplasms

NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

80 enrolled

Phase 3 Active not recruiting

Gastric Adenocarcinoma

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

757 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06519591 2026-02-18

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

40 enrolled

Phase 1 Active not recruiting

Stomach Neoplasms

NCT05867121 2026-02-02

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

102 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

80 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT07374250 2026-01-28

Huaxi

154 enrolled

Stomach Neoplasms

NCT06510010 2026-01-26

Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer

198 enrolled

Chemotherapy Effect

NCT07366528 2026-01-26

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Phase 3 Recruiting

387 enrolled

Phase 2/3 Active not recruiting

Neoplasms, Stomach Neoplasms

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

580 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT05026905 2026-01-20

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

66 enrolled

Pancreatic Neoplasms

NCT07038629 2026-01-07

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

52 enrolled

Esophageal Neoplasms

NCT03443492 2025-12-30

Pancreas

130 enrolled

Pancreatic Neoplasms

NCT07304258 2025-12-26

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

Gastric Cancer Peritoneal Metastases

NCT06576921 2025-12-23

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

116 enrolled

738 enrolled 22 charts 7 FDA

Stomach Neoplasms

NCT03615326 2025-12-11

MK-3475-811

Phase 3 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03013010 2025-12-08

PREACT

Phase 3 Completed

204 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT06584227 2025-12-08

ACPC

45 enrolled

Pancreatic cancer, adult, Pancreatic Neoplasms

NCT07243938 2025-11-24

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

70 enrolled

Colorectal Neoplasms

NCT07194005 2025-09-26

Remission

Stomach Neoplasms

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

208 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT05773092 2025-09-03

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Thoracic

NSCLC

NCT06732856 2025-07-28

NEO-CLAUD

Phase 1/2 Recruiting

57 enrolled

Stomach Neoplasms

NCT06048913 2025-07-04

Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

56 enrolled

Esophageal Neoplasms

NCT07025889 2025-06-18

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Phase 1/2 Recruiting

55 enrolled

Stomach Neoplasms

NCT07018063 2025-06-12

YOUNG-NEOS

35 enrolled

Neoplasms, Stomach Neoplasms

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

59 enrolled

Pan-tumor

NCT06988956 2025-05-25

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

95 enrolled

Esophageal Squamous Cell Carcinoma

NCT05593458 2025-04-09

TACTIC

Phase 3 Recruiting

190 enrolled

Stomach Neoplasms

NCT06914687 2025-04-06

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 4 Not yet recruiting

Esophageal Neoplasms, Stomach Neoplasms

NCT06779318 2025-04-03

Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis

464 enrolled

Pancreatic Neoplasms

NCT04195828 2025-04-01

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

106 enrolled

Phase 2 Enrolling by invitation

Advanced Gastric Cancer

NCT06901622 2025-03-30

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

50 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma

NCT06903273 2025-03-30

TisGCS for BTC

35 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06881017 2025-03-18

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

140 enrolled

Stomach Neoplasms

NCT04863430 2025-02-21

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Phase 2 Withdrawn

Stomach Neoplasms

NCT05586061 2025-02-07

RCTS

55 enrolled

HER2-positive Gastric Cancer

NCT06789679 2025-01-30

Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

128 enrolled

Pancreatic Adenocarcinoma

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

66 enrolled

Fruquintinib

NCT06657690 2025-01-10

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

56 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06664021 2025-01-10

Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

60 enrolled

Cholangiocarcinoma

NCT05218889 2024-12-31

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Phase 1/2 Recruiting

90 enrolled

Pancreatic Neoplasms

NCT06730373 2024-12-31

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

110 enrolled